BioCardia (NASDAQ: BCDA) SVP reports RSU vesting and option grant

Rhea-AI Filing Summary

BioCardia, Inc. Senior Vice President, Devices reported equity compensation activity. On December 8, 2025, the executive acquired 38,078 restricted stock units (RSUs), each equal to one share of common stock awarded as compensation in lieu of cash, with 100% of the RSUs vesting on that date. To cover income tax withholding for the vested RSUs, 15,172 shares were withheld by BioCardia, which is not a sale by the executive. After these transactions, the executive beneficially owned 31,874 shares of common stock. The filing also reports a grant of a stock option for 20,000 shares at an exercise price of $1.37 per share, expiring on December 8, 2035, vesting as to 1/48th of the shares starting January 8, 2026 and monthly thereafter, contingent on continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GILLIS EDWARD M

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CA 94085

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Devices

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/08/2025		A		38,078(1)	A	$1.37(1)	47,046	D
Common Stock	12/08/2025		F		15,172(2)	A	$1.37(2)	31,874	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.37	12/08/2025		A		20,000		(3)	12/08/2035	Common stock	20,000	$0	31,697	D

Explanation of Responses:

1. The reported securities represent restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock awarded as compensation in lieu of cash. 100% of the RSUs vested on December 8, 2025.

2. The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement of the RSUs vested on December 8, 2025 and does not represent a sale by the Reporting Person.

3. The option vests and becomes exercisable as to 1/48th of the shares on January 8, 2026, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date.

	/s/ David McClung, by power of attorney	12/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioCardia (BCDA) report in this Form 4?

The filing reports that a BioCardia Senior Vice President, Devices acquired 38,078 RSUs that fully vested on December 8, 2025, and received a stock option for 20,000 shares of common stock at an exercise price of $1.37 per share.

How many BioCardia (BCDA) shares does the reporting person own after these transactions?

Following the reported equity transactions, the executive beneficially owned 31,874 shares of BioCardia common stock and 31,697 derivative securities, including stock options.

Were any BioCardia (BCDA) shares actually sold by the insider in this Form 4?

No. The filing states that 15,172 shares were withheld by BioCardia to satisfy tax withholding obligations related to the RSU vesting, and this does not represent a sale by the reporting person.

What are the vesting terms of the BioCardia (BCDA) stock options granted?

The stock option for 20,000 shares at $1.37 per share vests and becomes exercisable as to 1/48th of the shares on January 8, 2026, and monthly thereafter, subject to the executive continuing as a service provider.

When do the reported BioCardia (BCDA) stock options expire?

The stock option reported in the filing has an expiration date of December 8, 2035, after which any unexercised portion will no longer be exercisable.

What role does the reporting person hold at BioCardia (BCDA)?

The reporting person is an Officer of BioCardia, serving as Senior Vice President, Devices, as indicated in the relationship section of the filing.